What is the projected market valuation for the Arthropod Born Viral Infections Market in 2035?

The projected market valuation for the Arthropod Born Viral Infections Market in 2035 is 3.517 USD Billion. Read More

What was the market valuation for the Arthropod Born Viral Infections Market in 2024?

The market valuation for the Arthropod Born Viral Infections Market in 2024 was 2.16 USD Billion. Read More

What is the expected CAGR for the Arthropod Born Viral Infections Market from 2025 to 2035?

The expected CAGR for the Arthropod Born Viral Infections Market during the forecast period 2025 - 2035 is 4.53%. Read More

Which companies are considered key players in the Arthropod Born Viral Infections Market?

Key players in the Arthropod Born Viral Infections Market include Bristol Myers Squibb, GSK, Sanofi, Merck & Co, Pfizer, Novartis, Bayer, AbbVie, and Regeneron Pharmaceuticals. Read More

What are the projected revenues for the Arboviruses segment in 2025?

The projected revenue for the Arboviruses segment in 2025 is 1.4 USD Billion. Read More

How does the revenue for Tick-borne infections compare to Midge-borne infections in 2025?

In 2025, the revenue for Tick-borne infections is projected at 0.696 USD Billion, whereas Midge-borne infections are expected to generate 1.081 USD Billion. Read More

What is the expected revenue for the Treatment segment in 2035?

The expected revenue for the Treatment segment in 2035 is projected to reach 1.22 USD Billion. Read More

What are the projected revenues for Molecular diagnostics in 2025?

The projected revenue for Molecular diagnostics in 2025 is 1.2 USD Billion. Read More

What is the revenue forecast for the Clinical Manifestation segment in 2035?

The revenue forecast for the Clinical Manifestation segment in 2035 is anticipated to be 0.069 USD Billion for both Rash and Encephalitis. Read More

How does the revenue for Serology in 2024 compare to its projection in 2035?

The revenue for Serology in 2024 was 0.86 USD Billion, and it is projected to increase to 1.4 USD Billion by 2035. Read More

Arthropod Born Viral Infections Market

ID: MRFR/HC/25129-HCR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

Arthropod Born Viral Infections Market Research Report By Type (Arboviruses, Arenaviruses, Bunyaviruses, Phleboviruses), By Transmission (Mosquito-borne, Tick-borne, Sandfly-borne, Midge-borne), By Clinical Manifestation (Fever, Rash, Encephalitis, Hemorrhagic fever), By Diagnosis (Serology, Molecular diagnostics, Culture), By Treatment (Antivirals, Supportive care, Vaccines) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Arthropod Born Viral Infections Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.53%

2024 Market Size$ 2.16 Billion

2025 Market Size$ 2.26 Billion

2035 Market Size$ 3.52 Billion

Key Players

Bristol Myers Squibb

GSK

Sanofi

Merck & Co

Pfizer

Novartis

Trends

Rising Incidence of Vector-Borne Diseases
Technological Advancements in Diagnostics and Treatment
Integrated Vector Management Strategies

Opportunities

Rising Global Travel and Trade
Emerging Research and Development
Government Initiatives and Funding

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 Arboviruses
  2. 4.1.2 Arenaviruses
  3. 4.1.3 Bunyaviruses
  4. 4.1.4 Phleboviruses
2. 4.2 Healthcare, BY Transmission (USD Billion)
  1. 4.2.1 Mosquito-borne
  2. 4.2.2 Tick-borne
  3. 4.2.3 Sandfly-borne
  4. 4.2.4 Midge-borne
3. 4.3 Healthcare, BY Clinical Manifestation (USD Billion)
  1. 4.3.1 Fever
  2. 4.3.2 Rash
  3. 4.3.3 Encephalitis
  4. 4.3.4 Hemorrhagic fever
4. 4.4 Healthcare, BY Diagnosis (USD Billion)
  1. 4.4.1 Serology
  2. 4.4.2 Molecular diagnostics
  3. 4.4.3 Culture
5. 4.5 Healthcare, BY Treatment (USD Billion)
  1. 4.5.1 Antivirals
  2. 4.5.2 Supportive care
  3. 4.5.3 Vaccines
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 GSK (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Sanofi (FR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bayer (DE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AbbVie (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Regeneron Pharmaceuticals (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY TRANSMISSION
5. 6.5 US MARKET ANALYSIS BY CLINICAL MANIFESTATION
6. 6.6 US MARKET ANALYSIS BY DIAGNOSIS
7. 6.7 US MARKET ANALYSIS BY TREATMENT
8. 6.8 CANADA MARKET ANALYSIS BY TYPE
9. 6.9 CANADA MARKET ANALYSIS BY TRANSMISSION
10. 6.10 CANADA MARKET ANALYSIS BY CLINICAL MANIFESTATION
11. 6.11 CANADA MARKET ANALYSIS BY DIAGNOSIS
12. 6.12 CANADA MARKET ANALYSIS BY TREATMENT
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY TRANSMISSION
16. 6.16 GERMANY MARKET ANALYSIS BY CLINICAL MANIFESTATION
17. 6.17 GERMANY MARKET ANALYSIS BY DIAGNOSIS
18. 6.18 GERMANY MARKET ANALYSIS BY TREATMENT
19. 6.19 UK MARKET ANALYSIS BY TYPE
20. 6.20 UK MARKET ANALYSIS BY TRANSMISSION
21. 6.21 UK MARKET ANALYSIS BY CLINICAL MANIFESTATION
22. 6.22 UK MARKET ANALYSIS BY DIAGNOSIS
23. 6.23 UK MARKET ANALYSIS BY TREATMENT
24. 6.24 FRANCE MARKET ANALYSIS BY TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY TRANSMISSION
26. 6.26 FRANCE MARKET ANALYSIS BY CLINICAL MANIFESTATION
27. 6.27 FRANCE MARKET ANALYSIS BY DIAGNOSIS
28. 6.28 FRANCE MARKET ANALYSIS BY TREATMENT
29. 6.29 RUSSIA MARKET ANALYSIS BY TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY TRANSMISSION
31. 6.31 RUSSIA MARKET ANALYSIS BY CLINICAL MANIFESTATION
32. 6.32 RUSSIA MARKET ANALYSIS BY DIAGNOSIS
33. 6.33 RUSSIA MARKET ANALYSIS BY TREATMENT
34. 6.34 ITALY MARKET ANALYSIS BY TYPE
35. 6.35 ITALY MARKET ANALYSIS BY TRANSMISSION
36. 6.36 ITALY MARKET ANALYSIS BY CLINICAL MANIFESTATION
37. 6.37 ITALY MARKET ANALYSIS BY DIAGNOSIS
38. 6.38 ITALY MARKET ANALYSIS BY TREATMENT
39. 6.39 SPAIN MARKET ANALYSIS BY TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY TRANSMISSION
41. 6.41 SPAIN MARKET ANALYSIS BY CLINICAL MANIFESTATION
42. 6.42 SPAIN MARKET ANALYSIS BY DIAGNOSIS
43. 6.43 SPAIN MARKET ANALYSIS BY TREATMENT
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY TRANSMISSION
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY CLINICAL MANIFESTATION
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TYPE
51. 6.51 CHINA MARKET ANALYSIS BY TRANSMISSION
52. 6.52 CHINA MARKET ANALYSIS BY CLINICAL MANIFESTATION
53. 6.53 CHINA MARKET ANALYSIS BY DIAGNOSIS
54. 6.54 CHINA MARKET ANALYSIS BY TREATMENT
55. 6.55 INDIA MARKET ANALYSIS BY TYPE
56. 6.56 INDIA MARKET ANALYSIS BY TRANSMISSION
57. 6.57 INDIA MARKET ANALYSIS BY CLINICAL MANIFESTATION
58. 6.58 INDIA MARKET ANALYSIS BY DIAGNOSIS
59. 6.59 INDIA MARKET ANALYSIS BY TREATMENT
60. 6.60 JAPAN MARKET ANALYSIS BY TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY TRANSMISSION
62. 6.62 JAPAN MARKET ANALYSIS BY CLINICAL MANIFESTATION
63. 6.63 JAPAN MARKET ANALYSIS BY DIAGNOSIS
64. 6.64 JAPAN MARKET ANALYSIS BY TREATMENT
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY TRANSMISSION
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY CLINICAL MANIFESTATION
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
70. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY TRANSMISSION
72. 6.72 MALAYSIA MARKET ANALYSIS BY CLINICAL MANIFESTATION
73. 6.73 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS
74. 6.74 MALAYSIA MARKET ANALYSIS BY TREATMENT
75. 6.75 THAILAND MARKET ANALYSIS BY TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY TRANSMISSION
77. 6.77 THAILAND MARKET ANALYSIS BY CLINICAL MANIFESTATION
78. 6.78 THAILAND MARKET ANALYSIS BY DIAGNOSIS
79. 6.79 THAILAND MARKET ANALYSIS BY TREATMENT
80. 6.80 INDONESIA MARKET ANALYSIS BY TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY TRANSMISSION
82. 6.82 INDONESIA MARKET ANALYSIS BY CLINICAL MANIFESTATION
83. 6.83 INDONESIA MARKET ANALYSIS BY DIAGNOSIS
84. 6.84 INDONESIA MARKET ANALYSIS BY TREATMENT
85. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY TRANSMISSION
87. 6.87 REST OF APAC MARKET ANALYSIS BY CLINICAL MANIFESTATION
88. 6.88 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS
89. 6.89 REST OF APAC MARKET ANALYSIS BY TREATMENT
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY TRANSMISSION
93. 6.93 BRAZIL MARKET ANALYSIS BY CLINICAL MANIFESTATION
94. 6.94 BRAZIL MARKET ANALYSIS BY DIAGNOSIS
95. 6.95 BRAZIL MARKET ANALYSIS BY TREATMENT
96. 6.96 MEXICO MARKET ANALYSIS BY TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY TRANSMISSION
98. 6.98 MEXICO MARKET ANALYSIS BY CLINICAL MANIFESTATION
99. 6.99 MEXICO MARKET ANALYSIS BY DIAGNOSIS
100. 6.100 MEXICO MARKET ANALYSIS BY TREATMENT
101. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY TRANSMISSION
103. 6.103 ARGENTINA MARKET ANALYSIS BY CLINICAL MANIFESTATION
104. 6.104 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS
105. 6.105 ARGENTINA MARKET ANALYSIS BY TREATMENT
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TRANSMISSION
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY CLINICAL MANIFESTATION
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY TRANSMISSION
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY CLINICAL MANIFESTATION
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY TRANSMISSION
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY CLINICAL MANIFESTATION
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
122. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY TRANSMISSION
124. 6.124 REST OF MEA MARKET ANALYSIS BY CLINICAL MANIFESTATION
125. 6.125 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS
126. 6.126 REST OF MEA MARKET ANALYSIS BY TREATMENT
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY TRANSMISSION, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY TRANSMISSION, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY CLINICAL MANIFESTATION, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY CLINICAL MANIFESTATION, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.2.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.2.5 BY TREATMENT, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.3.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.3.5 BY TREATMENT, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.4.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.4.5 BY TREATMENT, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.5.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.5.5 BY TREATMENT, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.6.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.6.5 BY TREATMENT, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.7.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.7.5 BY TREATMENT, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.8.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.8.5 BY TREATMENT, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.9.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.9.5 BY TREATMENT, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.10.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.10.5 BY TREATMENT, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.11.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.11.5 BY TREATMENT, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.12.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.12.5 BY TREATMENT, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.13.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.13.5 BY TREATMENT, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.14.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.14.5 BY TREATMENT, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.15.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.15.5 BY TREATMENT, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.16.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.16.5 BY TREATMENT, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.17.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.17.5 BY TREATMENT, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.18.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.18.5 BY TREATMENT, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.19.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.19.5 BY TREATMENT, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.20.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.20.5 BY TREATMENT, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.21.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.21.5 BY TREATMENT, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.22.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.22.5 BY TREATMENT, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.23.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.23.5 BY TREATMENT, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.24.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.24.5 BY TREATMENT, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.25.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.25.5 BY TREATMENT, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.26.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.26.5 BY TREATMENT, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.27.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.27.5 BY TREATMENT, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.28.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.28.5 BY TREATMENT, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.29.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.29.5 BY TREATMENT, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY TRANSMISSION, 2025-2035 (USD Billion)
  3. 7.30.3 BY CLINICAL MANIFESTATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY DIAGNOSIS, 2025-2035 (USD Billion)
  5. 7.30.5 BY TREATMENT, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Arthropod Born Viral Infections Market Segmentation

Arthropod Born Viral Infections Market By Type (USD Billion, 2025-2035)

Arboviruses
Arenaviruses
Bunyaviruses
Phleboviruses

Arthropod Born Viral Infections Market By Transmission (USD Billion, 2025-2035)

Mosquito-borne
Tick-borne
Sandfly-borne
Midge-borne

Arthropod Born Viral Infections Market By Clinical Manifestation (USD Billion, 2025-2035)

Fever
Rash
Encephalitis
Hemorrhagic fever

Arthropod Born Viral Infections Market By Diagnosis (USD Billion, 2025-2035)

Serology
Molecular diagnostics
Culture

Arthropod Born Viral Infections Market By Treatment (USD Billion, 2025-2035)

Antivirals
Supportive care
Vaccines

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”